EYA2 and breast cancer: Recently, it has been found that EYA2 Tyr phosphatase inhibitors could reduce the mesenchymal phenotype, enhance the immunogenicity of tumor cells, weaken tumor growth, and increase the antitumor effects of anti-PD-1 in the mouse BC model by targeting FBOX7.